Ms. Linda Kisa reports

CRESCITA THERAPEUTICS ANNOUNCES MUTUAL TERMINATION OF LICENSING AGREEMENT WITH CROMA PHARMA GMBH FOR PLIAGLIS

Crescita Therapeutics Inc. has, by mutual agreement, terminated its commercialization and development licence agreement with Croma Pharma GmbH, which granted Croma exclusive rights to market Pliaglis in Germany, the United Kingdom, Ireland, Switzerland, Brazil, Romania, Belgium, the Netherlands and Luxembourg.

Following a strategic business review, Croma decided to rationalize its product portfolio and realign its business priorities. Under the terms of the termination agreement, Crescita will regain all development and commercialization rights for Pliaglis in the territories, and Croma will pay the company 575,000 euros (approximately $900,000). Crescita plans to explore potential new partnerships to commercialize Pliaglis in the territories.

About Crescita Therapeutics Inc.

Crescita is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D (research and development) and manufacturing capabilities. The company offers a portfolio of high-quality, science-based, non-prescription skin care products and early- to commercial-stage prescription products. Crescita also owns multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin.

We seek Safe Harbor.